KRAS and neoplasm: In brief, we injected mutant KRAS A549 (G12S) cells into the flanks of athymic mice to establish xenografts, randomly assigned mice to vehicle control (n = 7) or 249C-recipient groups (n = 7; 10 mg kg−1) with twice daily intraperitoneal (i.p.)injections, and recorded tumor volume and body weight over time.